JP2024524880A5 - - Google Patents
Info
- Publication number
- JP2024524880A5 JP2024524880A5 JP2023575897A JP2023575897A JP2024524880A5 JP 2024524880 A5 JP2024524880 A5 JP 2024524880A5 JP 2023575897 A JP2023575897 A JP 2023575897A JP 2023575897 A JP2023575897 A JP 2023575897A JP 2024524880 A5 JP2024524880 A5 JP 2024524880A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208478P | 2021-06-08 | 2021-06-08 | |
| US63/208,478 | 2021-06-08 | ||
| US202263343268P | 2022-05-18 | 2022-05-18 | |
| US63/343,268 | 2022-05-18 | ||
| PCT/US2022/032482 WO2022261079A2 (en) | 2021-06-08 | 2022-06-07 | Proteins that bind cd80 and/or cd86, and ox40l |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524880A JP2024524880A (ja) | 2024-07-09 |
| JP2024524880A5 true JP2024524880A5 (enExample) | 2025-06-16 |
Family
ID=84426420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575897A Pending JP2024524880A (ja) | 2021-06-08 | 2022-06-07 | Ｃｄ８０および／またはｃｄ８６とｏｘ４０ｌに結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240262922A1 (enExample) |
| EP (1) | EP4351644A4 (enExample) |
| JP (1) | JP2024524880A (enExample) |
| KR (1) | KR20240019224A (enExample) |
| AU (1) | AU2022290257A1 (enExample) |
| BR (1) | BR112023025553A2 (enExample) |
| CA (1) | CA3218785A1 (enExample) |
| IL (1) | IL309119A (enExample) |
| MX (1) | MX2023014695A (enExample) |
| TW (1) | TW202315890A (enExample) |
| WO (1) | WO2022261079A2 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007648A1 (fr) * | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
| US9574002B2 (en) * | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
| US20140370012A1 (en) * | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
| JP7628764B2 (ja) * | 2015-09-29 | 2025-02-12 | アムジエン・インコーポレーテツド | Ａｓｇｒ阻害剤 |
| WO2020192709A1 (en) * | 2019-03-27 | 2020-10-01 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific polypeptide complexes |
-
2022
- 2022-06-07 JP JP2023575897A patent/JP2024524880A/ja active Pending
- 2022-06-07 WO PCT/US2022/032482 patent/WO2022261079A2/en not_active Ceased
- 2022-06-07 EP EP22820886.4A patent/EP4351644A4/en active Pending
- 2022-06-07 TW TW111121114A patent/TW202315890A/zh unknown
- 2022-06-07 CA CA3218785A patent/CA3218785A1/en active Pending
- 2022-06-07 MX MX2023014695A patent/MX2023014695A/es unknown
- 2022-06-07 BR BR112023025553A patent/BR112023025553A2/pt unknown
- 2022-06-07 KR KR1020247000142A patent/KR20240019224A/ko active Pending
- 2022-06-07 AU AU2022290257A patent/AU2022290257A1/en active Pending
- 2022-06-07 IL IL309119A patent/IL309119A/en unknown
-
2023
- 2023-12-06 US US18/530,536 patent/US20240262922A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230287134A1 (en) | Antibody molecules which bind cd45 | |
| US12173046B2 (en) | TNFR2 agonists with improved stability | |
| BR112020002012A2 (pt) | anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
| JP2021072810A (ja) | 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体 | |
| CA2992372A1 (en) | Antibody molecules which bind cd22 | |
| EP3271395A1 (en) | Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof | |
| TW201900211A (zh) | 一種pd-l1抗體藥物組合物及其用途 | |
| JP2023538367A (ja) | マルチパラトピック抗ｐｄ－１抗体およびその用途 | |
| JP2023538098A5 (enExample) | ||
| AU2016290523A1 (en) | Fusion proteins which bind to human Fc receptors | |
| JP2025146842A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| JP2022517809A (ja) | Ｌｉｌｒｂ３結合分子とその使用 | |
| EP4426719A1 (en) | Novel proteins | |
| JP2024515607A (ja) | 抗炎症性シグレックタンパク質ならびにその製造方法及び使用方法 | |
| RU2023135361A (ru) | Белки, которые связываются с cd80 и/или cd86 и ox40l | |
| US20250313644A1 (en) | Antibodies capable of specifically binding tl1a and use thereof | |
| US20240262922A1 (en) | Proteins that bind cd80 and/or cd86, and ox40l | |
| HK40129548A (en) | Antibodies capable of specifically binding tnf‑like ligand 1a and use thereof | |
| WO2026082110A1 (zh) | 抗pacap抗体及其应用 | |
| CA3300482A1 (en) | An antibody and pharmaceutical composition for treating immune diseases comprising the same | |
| HK40111520A (zh) | 结合cd80和/或cd86，以及ox40l的蛋白质 | |
| HK40072147B (en) | Tnfr2 agonists with improved stability | |
| HK40072147A (en) | Tnfr2 agonists with improved stability | |
| BR122021004223B1 (pt) | Molécula de anticorpo, composição, sequência de nucleotídeo, vetor, molécula de anticorpo e uso de uma molécula de anticorpo |